<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05024851</url>
  </required_header>
  <id_info>
    <org_study_id>PRURINEURO (29BRC21.0135)</org_study_id>
    <nct_id>NCT05024851</nct_id>
  </id_info>
  <brief_title>Psychogenic and Neurogenic Components in Patients With Psychogenic or Neuropathic Pruritus</brief_title>
  <acronym>PRURINEURO</acronym>
  <official_title>Psychogenic and Neurogenic Components in Patients With Psychogenic or Neuropathic Pruritus : PRURINEURO, a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scientific research on pruritus is in intensive development, with significant advances in&#xD;
      understanding its pathophysiology. The causes of pruritus are very huge; they can be&#xD;
      classified into different categories; we can find dermatological causes, systemic causes,&#xD;
      neuropathic or neurological causes, psychogenic or even idiopathic causes.&#xD;
&#xD;
      The diagnosis of psychogenic pruritus is often over stated, when no cause is found;&#xD;
      therefore, it is important to see what is really relieving from psychic so as not to&#xD;
      over-diagnose and adopt a therapy more in line with the real problem of the patient. In daily&#xD;
      practice, it seems to have a tendency to separate psychogenic and neurogenic etiologies in&#xD;
      the diagnosis of neuropathic or psychogenic pruritus.&#xD;
&#xD;
      In the case of patients with psychogenic pruritus and neuropathic pruritus, no study has&#xD;
      attempted to study the respective part of psychogenic and neurogenic components.&#xD;
      Consequently, it would therefore be interesting to assess the areas of superposition and&#xD;
      distinction of neuropathic and psychogenic pruritus.&#xD;
&#xD;
      The aim of this pilot study is to assess the psychogenic and neurogenic components of&#xD;
      psychogenic pruritus and neuropathic pruritus in order to improve understanding of the&#xD;
      mechanism and therefore their management.&#xD;
&#xD;
      The main objective of this study is to highlight the differences and the potential common&#xD;
      characteristics between psychogenic and neuropathic pruritus in order to improve the&#xD;
      differential diagnosis between these two pathologies.&#xD;
&#xD;
      The secondary objective of this study is to describe the psychogenic and neurogenic&#xD;
      characteristics of psychogenic and neuropathic pruritus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PruriNeuro : Non-interventional single-center prospective study organized and practiced on&#xD;
      humans for the development of medical knowledge, in which the data are obtained by validated&#xD;
      questionnaires.&#xD;
&#xD;
      The duration of participation is estimated at 1 hour.&#xD;
&#xD;
      Questionnaires used :&#xD;
&#xD;
        -  Critères diagnostiques du prurit psychogène (Diagnosis criteria of functional itch&#xD;
           disorder or psychogenic pruritus, from the French psychodermatology group)&#xD;
&#xD;
        -  NP5 questionnaire&#xD;
&#xD;
        -  Questionnaire de Brest&#xD;
&#xD;
        -  HADS&#xD;
&#xD;
        -  TAS-20&#xD;
&#xD;
        -  DN4i&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 25, 2021</start_date>
  <completion_date type="Anticipated">August 25, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Questionnaire de Brest</measure>
    <time_frame>at the enrollment</time_frame>
    <description>Qualitative assessment of pruritus, specifying the chronology, location, intensity, characteristics and effect on daily activities of the itching induced by pruritus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HADS (Hospital Anxiety and Depression Scale)</measure>
    <time_frame>at the enrollment</time_frame>
    <description>Total score for Depression or Anxiety 0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NP5</measure>
    <time_frame>at the enrollment</time_frame>
    <description>A score of two criteria out of five is optimal to discriminate Neuropathic pruritus (NP) from Non-NP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TAS-20</measure>
    <time_frame>at the enrollment</time_frame>
    <description>The TAS-20 is a self-report scale that is comprised of 20 items. Items are rated using a 5-point Likert scale whereby 1 = strongly disagree and 5 = strongly agree. There are 5 items that are negatively keyed (items 4, 5, 10, 18 and 19). The total alexithymia score is the sum of responses to all 20 items, while the score for each subscale factor is the sum of the responses to that subscale. The TAS-20 uses cutoff scoring: equal to or less than 51 = non-alexithymia, equal to or greater than 61 = alexithymia. Scores of 52 to 60 = possible alexithymia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>DN4i</measure>
    <time_frame>at the enrollment</time_frame>
    <description>score equal to or greater than 3 : in favor of neuropathic pruritus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnosis criteria of functional itch disorder or psychogenic pruritus, from the French psychodermatology group</measure>
    <time_frame>at the enrollment</time_frame>
    <description>three compulsory criteria; Three additional criteria from seven items should also be present</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Pruritus</condition>
  <condition>Psychogenic Skin Disease</condition>
  <condition>Neuropathic Pain</condition>
  <condition>Itch</condition>
  <arm_group>
    <arm_group_label>Patients with Psychogenic pruritus</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with Neuropathic Pruritus</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Evaluation of the Psychogenic and Neurogenic Components using questionnaires</description>
    <arm_group_label>Patients with Neuropathic Pruritus</arm_group_label>
    <arm_group_label>Patients with Psychogenic pruritus</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with neuropathic or psychogenic pruritus consulting in the dermatology department&#xD;
        of the CHRU de Brest.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major (&gt; 18 years old)&#xD;
&#xD;
          -  Diagnosis of psychogenic pruritus or neuropathic pruritus made in consultation, in day&#xD;
             hospital or in hospital, within the dermatology department at the CHRU de Brest&#xD;
&#xD;
          -  Able to understand and agree to sign the information and non-opposition notice&#xD;
&#xD;
          -  No opposition of the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under legal protection (guardianship, curatorship)&#xD;
&#xD;
          -  Minor (&lt;18 years old)&#xD;
&#xD;
          -  Acute or chronic condition which could limit the patient's ability to the study's&#xD;
             participation&#xD;
&#xD;
          -  Inability to understand and sign the information and non-opposition notice&#xD;
&#xD;
          -  Refusal to give no opposition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurent Misery</last_name>
    <phone>0298883527</phone>
    <email>laurent.misery@chu-brest.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie Brenaut</last_name>
    <email>emilie.brenuat@chu-brest.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent Miresy</last_name>
      <email>laurent.misery@chu-brest.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psychogenic Pruritus</keyword>
  <keyword>Neuropathic Pruritus</keyword>
  <keyword>Psychogenic Component</keyword>
  <keyword>Neurogenic Component</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All collected data that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data will be available beginning two years and ending five years following the publication</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

